CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Citius Pharmaceuticals, Inc. - CTXR CFD

0.7676
0.8%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0157
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Citius Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.7839
Open* 0.7676
1-Year Change* -53.05%
Day's Range* 0.7676 - 0.779
52 wk Range 0.60-1.71
Average Volume (10 days) 678.56K
Average Volume (3 months) 11.89M
Market Cap 119.23M
P/E Ratio -100.00K
Shares Outstanding 158.97M
Revenue N/A
EPS -0.22
Dividend (Yield %) N/A
Beta 1.44
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 0.7839 -0.0137 -1.72% 0.7976 0.8177 0.7676
Apr 11, 2024 0.8275 -0.0226 -2.66% 0.8501 0.8626 0.7476
Apr 10, 2024 0.8475 -0.0001 -0.01% 0.8476 0.8676 0.8279
Apr 9, 2024 0.8877 -0.0599 -6.32% 0.9476 0.9586 0.8581
Apr 8, 2024 0.9580 -0.0096 -0.99% 0.9676 0.9876 0.9476
Apr 5, 2024 0.9976 0.0800 8.72% 0.9176 1.0076 0.8977
Apr 4, 2024 0.9391 -0.0185 -1.93% 0.9576 0.9626 0.9110
Apr 3, 2024 0.9577 -0.0069 -0.72% 0.9646 0.9976 0.9414
Apr 2, 2024 0.9709 -0.0767 -7.32% 1.0476 1.0576 0.9276
Apr 1, 2024 1.0076 0.1002 11.04% 0.9074 1.0576 0.8978
Mar 28, 2024 0.8880 0.0853 10.63% 0.8027 0.9276 0.8026
Mar 27, 2024 0.8144 0.0278 3.53% 0.7866 0.8269 0.7726
Mar 26, 2024 0.8011 -0.0105 -1.29% 0.8116 0.8117 0.7676
Mar 25, 2024 0.8030 0.0256 3.29% 0.7774 0.8361 0.7676
Mar 22, 2024 0.7843 0.0388 5.20% 0.7455 0.7846 0.7186
Mar 21, 2024 0.7477 -0.0269 -3.47% 0.7746 0.7752 0.7406
Mar 20, 2024 0.7677 0.0401 5.51% 0.7276 0.7774 0.7276
Mar 19, 2024 0.7389 0.0113 1.55% 0.7276 0.7494 0.7178
Mar 18, 2024 0.7249 0.0173 2.44% 0.7076 0.7966 0.6976
Mar 15, 2024 0.7260 0.0479 7.06% 0.6781 0.7360 0.6781

Citius Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Friday, May 10, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Citius Pharmaceuticals Inc Earnings Release
Q2 2024 Citius Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Monday, August 12, 2024

Time (UTC)

10:59

Country

US

Event

Q3 2024 Citius Pharmaceuticals Inc Earnings Release
Q3 2024 Citius Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 33.3161 23.3653 17.7107 15.5984 13.3391
Selling/General/Admin. Expenses, Total 15.6606 11.2914 8.89788 7.00146 7.22622
Research & Development 17.6555 12.2405 8.81281 8.5969 6.56293
Operating Income -33.3161 -23.3653 -17.7107 -15.5984 -13.3391
Interest Income (Expense), Net Non-Operating 0.2514 0.25099 0.0524 0.03622 -0.01584
Net Income Before Taxes -33.0647 -23.0544 -17.5481 -15.5621 -12.5366
Net Income After Taxes -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Net Income Before Extra. Items -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Net Income -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Income Available to Common Excl. Extra. Items -33.6407 -24.5053 -17.5481 -15.5621 -12.5366
Income Available to Common Incl. Extra. Items -33.6407 -24.5053 -17.5481 -15.5621 -12.5366
Diluted Net Income -33.6407 -24.5053 -17.5481 -15.5621 -12.5366
Diluted Weighted Average Shares 146.082 108.599 39.1652 20.1618 10.7319
Diluted EPS Excluding Extraordinary Items -0.23029 -0.22565 -0.44805 -0.77186 -1.16817
Diluted Normalized EPS -0.23029 -0.22718 -0.44805 -0.77186 -1.2101
Unusual Expense (Income) 0 -0.16656 0 -0.45
Other, Net 0 0.05992 0.11021 0 0.81834
Total Adjustments to Net Income 0 -1.45088
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 8.67211 10.6853 3.66419 7.54957 8.91665
Selling/General/Admin. Expenses, Total 4.90744 5.95845 3.80437 3.69234 4.02846
Research & Development 3.76468 4.72686 3.44552 3.85723 4.88819
Operating Income -8.67211 -10.6853 -3.66419 -7.54957 -8.91665
Interest Income (Expense), Net Non-Operating 0.33678 0.30328 0.21455 0.13483 0.05302
Other, Net 0 0
Net Income Before Taxes -8.33533 -10.382 -3.44965 -7.41474 -8.86363
Net Income After Taxes -8.47933 -10.526 -3.59365 -7.99074 -8.86363
Net Income Before Extra. Items -8.47933 -10.526 -3.59365 -7.99074 -8.86363
Net Income -8.47933 -10.526 -3.59365 -7.99074 -8.86363
Income Available to Common Excl. Extra. Items -8.47933 -10.526 -3.59365 -7.99074 -8.86363
Income Available to Common Incl. Extra. Items -8.47933 -10.526 -3.59365 -7.99074 -8.86363
Diluted Net Income -8.47933 -10.526 -3.59365 -7.99074 -8.86363
Diluted Weighted Average Shares 153.775 146.252 146.211 146.146 146.13
Diluted EPS Excluding Extraordinary Items -0.05514 -0.07197 -0.02458 -0.05468 -0.06066
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.05514 -0.07197 -0.04052 -0.05468 -0.06066
Total Adjustments to Net Income 0 0
Unusual Expense (Income) 0 0 -3.58569 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 44.5643 72.8143 13.982 7.94192 10.0601
Cash and Short Term Investments 41.7117 70.073 13.8597 7.8938 9.184
Cash & Equivalents 41.7117 70.073 13.8597 7.8938 9.184
Prepaid Expenses 2.85258 2.7414 0.12224 0.04811 0.05773
Total Assets 113.999 142.429 43.7737 36.7464 31.0505
Property/Plant/Equipment, Total - Net 0.65017 0.82985 0.98778 0.00059 0.00148
Property/Plant/Equipment, Total - Gross
Accumulated Depreciation, Total
Goodwill, Net 9.3468 9.3468 9.3468 9.3468 1.5868
Intangibles, Net 59.4 59.4 19.4 19.4 19.4
Other Long Term Assets, Total 0.03806 0.03806 0.05709 0.05709 0.00217
Total Current Liabilities 4.53001 3.98229 4.09713 4.60772 3.18484
Accounts Payable 1.16538 1.2771 1.85624 2.71354 1.57344
Accrued Expenses 3.36463 2.7052 2.06793 1.72121 1.43843
Notes Payable/Short Term Debt 0 0 0.17297 0.17297 0.17297
Other Current Liabilities, Total 0
Total Liabilities 11.1734 10.2467 10.103 9.59352 3.18484
Total Long Term Debt 0 0 0.16458 0 0
Total Equity 102.826 132.182 33.6707 27.1529 27.8657
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.14621 0.14598 0.05558 0.02893 0.0162
Additional Paid-In Capital 232.368 228.084 104.209 80.1697 68.1073
Retained Earnings (Accumulated Deficit) -129.688 -96.0478 -70.5939 -53.0458 -40.2578
Total Liabilities & Shareholders’ Equity 113.999 142.429 43.7737 36.7464 31.0505
Total Common Shares Outstanding 146.211 145.979 55.577 28.9305 16.1988
Total Receivables, Net 0.81834
Long Term Debt 0 0.16458 0
Deferred Income Tax 5.5618 4.9858 4.9858 4.9858
Other Liabilities, Total 0.48125 0.67823 0.85547
Minority Interest 0.60038 0.60038
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 41.1142 34.9011 42.3174 44.5643 50.8345
Cash and Short Term Investments 33.2818 29.0655 36.8872 41.7117 48.0442
Cash & Equivalents 33.2818 29.0655 36.8872 41.7117 48.0442
Prepaid Expenses 7.83232 5.8356 5.43013 2.85258 2.79032
Total Assets 110.405 104.241 111.705 113.999 120.316
Property/Plant/Equipment, Total - Net 0.50583 0.55484 0.60299 0.65017 0.69642
Goodwill, Net 9.3468 9.3468 9.3468 9.3468 9.3468
Intangibles, Net 59.4 59.4 59.4 59.4 59.4
Other Long Term Assets, Total 0.03806 0.03806 0.03806 0.03806 0.03806
Total Current Liabilities 5.79086 6.20968 4.53717 4.53001 4.46112
Accounts Payable 3.07967 2.72559 1.53758 1.16538 1.69052
Accrued Expenses 2.71119 3.48408 2.99959 3.36463 2.7706
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 12.7051 13.0347 11.2719 11.1734 10.5802
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Deferred Income Tax 5.9938 5.8498 5.7058 5.5618 4.9858
Minority Interest 0.60038 0.60038 0.60038 0.60038 0.60038
Other Liabilities, Total 0.32001 0.37483 0.42857 0.48125 0.53288
Total Equity 97.6998 91.2061 100.433 102.826 109.736
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.15886 0.14636 0.14621 0.14621 0.14613
Additional Paid-In Capital 249.828 234.868 233.569 232.368 231.287
Retained Earnings (Accumulated Deficit) -152.287 -143.808 -133.282 -129.688 -121.698
Total Liabilities & Shareholders’ Equity 110.405 104.241 111.705 113.999 120.316
Total Common Shares Outstanding 158.858 146.358 146.211 146.211 146.13
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Cash From Operating Activities -28.3613 -24.2504 -16.9307 -12.4377 -11.3181
Cash From Operating Activities 0.00292 0.00149 0.00084 0.00089 0.00175
Non-Cash Items 4.46091 1.5198 1.48355 0.92758 0.7069
Cash Taxes Paid
Cash Interest Paid 0 0.00019
Changes in Working Capital 0.23956 -2.71727 -0.86697 2.19592 0.50985
Cash From Investing Activities 0 -40.0069 -0.00183 0 0
Other Investing Cash Flow Items, Total 0
Cash From Financing Activities 0 120.471 22.8984 11.1475 17.298
Financing Cash Flow Items 0 18.4504 0 0
Issuance (Retirement) of Debt, Net 0 -0.17297 0.16458 0 0
Net Change in Cash -28.3613 56.2132 5.96594 -1.2902 5.9799
Capital Expenditures 0 -40.0069 -0.00183 0 0
Issuance (Retirement) of Stock, Net 0 102.193 22.7339 11.1475 17.298
Deferred Taxes 0.576
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -14.1197 -3.59365 -33.6407 -25.6499 -16.7863
Cash From Operating Activities -12.6774 -4.82444 -28.3613 -22.0287 -14.3167
Cash From Operating Activities 0.00146 0.00073 0.00292 0.00219 0.00146
Non-Cash Items 2.56255 1.24754 4.46091 3.3344 2.28611
Changes in Working Capital -1.40977 -2.62306 0.23956 0.28456 0.18199
Cash From Financing Activities 0.03127 0 0 0 0
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0.03127 0 0 0
Issuance (Retirement) of Debt, Net 0 0 0
Net Change in Cash -12.6462 -4.82444 -28.3613 -22.0287 -14.3167
Cash From Investing Activities 0 0 0
Capital Expenditures 0 0
Deferred Taxes 0.288 0.144 0.576
Other Investing Cash Flow Items, Total 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Citius Pharmaceuticals, Inc. Company profile

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution for treating patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering with hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, a engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Industry: Biotechnology & Medical Research (NEC)

11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

BTC/USD

65,246.75 Price
+2.520% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.51 Price
+3.950% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,184.99 Price
+3.970% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,022.60 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading